Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The best results are obtained when combined with a healthy diet and regular exercise
Trim RX and the Compounding Niche TrimRX remains firmly in the compounding space
GLP-1 Receptor Pathway - Reduces hunger drive centrally (hypothalamus, brainstem) - Decreases the reward value of food (mesolimbic system) - Enhances glucose-dependent insulin secretion - Slows gastric emptying Amylin Receptor Pathway - Induces satiety through the area postrema and NTS - Activates POMC neurons (pro-satiety) and suppresses NPY/AgRP neurons (pro-hunger) in the arcuate nucleus - Additional gastric emptying delay through distinct neural circuits - Suppresses post-prandial glucagon secretion - May contribute to leptin resensitization The combination of these two pathways produces what researchers describe as broader modulation of neuroendocrine appetite control meaning amycretin hits more of the biological switches that drive eating behavior than a GLP-1-only drug can reach
Tang ST, Tang HQ, Su H, et al
The clinical profile of BPC-157, including how it compares to TB-500 and when the two are combined at our Doral clinic, is in our complete BPC-157 guide
What distinguishes the GLP-1 research is several converging factors that increase confidence in the findings
